Celastrol mitigates staphyloxanthin biosynthesis and biofilm formation in Staphylococcus aureus via targeting key regulators of virulence; in vitro and in vivo approach

Abstract

Background Staphylococcus aureus is a leading cause of human infections. The spread of antibiotic-resistant staphylococci has driven the search for novel strategies to supersede antibiotics use. Thus, targeting bacterial virulence rather than viability could be a possible alternative. Results The influence of celastrol on staphyloxanthin (STX) biosynthesis, biofilm formation, antibiotic susceptibility and host pathogenesis in S. aureus has been investigated. Celastrol efficiently reduced STX biosynthesis in S. aureus. Liquid chromatography-mass spectrometry (LC–MS) and molecular docking revealed that celastrol inhibits STX biosynthesis through its effect on CrtM. Quantitative measurement of STX intermediates showed a significant pigment inhibition via interference of celastrol with CrtM and accumulation of its substrate, farnesyl diphosphate. Importantly, celastrol-treated S. aureus was more sensitive to environmental stresses and human blood killing than untreated bacteria. Similarly, inhibition of STX upon celastrol treatment rendered S. aureus more susceptible to membrane targeting antibiotics. In addition to its anti-pigment capability, celastrol exhibits significant anti-biofilm activity against S. aureus as indicated by crystal violet assay and microscopy. Celastrol-treated cells showed deficient exopolysaccharide production and cell hydrophobicity. Moreover, celastrol markedly synergized the action of conventional antibiotics against S. aureus and reduced bacterial pathogenesis in vivo using mice infection model. These findings were further validated using qRT-PCR, demonstrating that celastrol could alter the expression of STX biosynthesis genes as well as biofilm formation related genes and bacterial virulence. Conclusions Celastrol is a novel anti-virulent agent against S. aureus suggesting, a prospective therapeutic role for celastrol as a multi-targeted anti-pathogenic agent.

Geraniol inhibits biofilm formation of methicillin-resistant Staphylococcus aureus and increase the therapeutic effect of vancomycin in vivo

“…Therefore, we selected several core genes for this study and found that they were significantly downregulated under the influence of geraniol. This is in agreement with phenotypic experiments ( Zhang et al, 2021 ; Yehia et al, 2022 ).…”

Celastrol Combats Methicillin‐Resistant Staphylococcus aureus by Targeting Δ1‐Pyrroline‐5‐Carboxylate Dehydrogenase

“…The multi-omics analysis demonstrated that celastrol affected multiple metabolic pathways, including glycolysis, fatty acid metabolism, and the two-component system. Among them, carotenoid biosynthesis related to staphyloxanthin was inhibited after celastrol treatment, which was consistent with the results of a recent study by Yehia et al [45] Celastrol has been reported to exhibit anti-biofilm properties toward MRSA. [45] Results of the multi-omics analysis have led us to speculate this may be because celastrol can inhibit QS and TCS.…”

Recent advances in the discovery of plant-derived antimicrobial natural products to combat antimicrobial resistant pathogens: insights from 2018–2022

“…151 In S. aureus , celastrol inhibits a virulence factor called carotenoid staphyloxanthin (STX) which is essential for S. aureus to disrupt reactive oxygen species produced by host macrophages and neutrophils, thus reducing bacterial clearance by the innate immune system. 152…”